HCP Preferences for Biosimilar Disclosures
| % Preference among Those Assigned to Disclosure Condition | % Preference among Those Not Assigned to Disclosure Condition | |
|---|---|---|
| KESTERIN is a biosimilar. | 12.3% | 8.5% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing reference product. | 35.0% | 32.6% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from MYTROZEN, an existing FDA-approved reference product. | 46.1% | 51.7% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. Biosimilars are made from the same types of sources as the FDA-approved reference product. | 39.9% | 41.7% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from MYTROZEN, an existing FDA-approved reference product. This biosimilar is made from the same types of sources as MYTROZEN. | 48.6% | 58.0% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. Biosimilars are made from the same types of sources as the FDA-approved reference product. KESTERIN has the same route of administration, dosage form, and strength as an existing FDA-approved reference product | 54.8% | 62.8% |
| KESTERIN is a biosimilar. This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from MYTROZEN, an existing FDA-approved reference product. This biosimilar is made from the same types of sources as MYTROZEN. KESTERIN has the same route of administration, dosage form, and strength as MYTROZEN. | 73.2% | 72.8% |
Abbreviation: HCP, Health care providers.